DE69941263D1 - Zusammensetzungen zur vorbeugung und behandlung der artheriosklerose und der restenose nach ptca - Google Patents

Zusammensetzungen zur vorbeugung und behandlung der artheriosklerose und der restenose nach ptca

Info

Publication number
DE69941263D1
DE69941263D1 DE69941263T DE69941263T DE69941263D1 DE 69941263 D1 DE69941263 D1 DE 69941263D1 DE 69941263 T DE69941263 T DE 69941263T DE 69941263 T DE69941263 T DE 69941263T DE 69941263 D1 DE69941263 D1 DE 69941263D1
Authority
DE
Germany
Prior art keywords
prevention
treatment
ptca
restenosis
artherosclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69941263T
Other languages
English (en)
Inventor
Takashi Muramatsu
Kenji Kadomatsu
Mitsuru Horiba
Shinya Ikematsu
Sadatoshi Sakuma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anagenics Ltd
Original Assignee
Medical Therapies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Therapies Ltd filed Critical Medical Therapies Ltd
Application granted granted Critical
Publication of DE69941263D1 publication Critical patent/DE69941263D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69941263T 1998-08-24 1999-08-24 Zusammensetzungen zur vorbeugung und behandlung der artheriosklerose und der restenose nach ptca Expired - Lifetime DE69941263D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP25181298 1998-08-24
PCT/JP1999/004550 WO2000010608A1 (fr) 1998-08-24 1999-08-24 Medicament pour le traitement et/ou la prevention de l'arteriosclerose et de la reangiostenose post-actp

Publications (1)

Publication Number Publication Date
DE69941263D1 true DE69941263D1 (de) 2009-09-24

Family

ID=17228295

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69941263T Expired - Lifetime DE69941263D1 (de) 1998-08-24 1999-08-24 Zusammensetzungen zur vorbeugung und behandlung der artheriosklerose und der restenose nach ptca

Country Status (10)

Country Link
US (2) US7309695B2 (de)
EP (1) EP1108436B1 (de)
JP (1) JP4228111B2 (de)
KR (1) KR100608276B1 (de)
CN (1) CN1222296C (de)
AT (1) ATE439146T1 (de)
AU (1) AU762437B2 (de)
CA (1) CA2341638C (de)
DE (1) DE69941263D1 (de)
WO (1) WO2000010608A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8106009B2 (en) * 1997-09-26 2012-01-31 Medical Therapies Limited Pharmaceutical composition for preventing or treating ischemic diseases
JP4768440B2 (ja) 2003-03-06 2011-09-07 セルミド リミテッド 開腹手術後の癒着の予防剤
US20060085062A1 (en) * 2003-11-28 2006-04-20 Medlogics Device Corporation Implantable stent with endothelialization factor
CN100434521C (zh) * 2004-12-28 2008-11-19 湖州市中心医院 中期因子基因为靶的反义寡核苷酸的结构和用途
WO2006126600A1 (ja) * 2005-05-25 2006-11-30 National University Corporation Nagoya Universtiy 血管閉塞性疾患用医薬組成物
EP2803674A3 (de) 2006-11-14 2014-12-24 Medical Therapies Limited Antikörper zur Erkennung der C-Domäne von Midkin
TWI481713B (zh) 2006-11-14 2015-04-21 Ribomic Inc 對中期因子之適體及其使用
EP2686016B1 (de) 2011-03-14 2019-05-01 Cellmid Limited Antikörper zur erkennung der n-domäne von midkin
AU2013297478B2 (en) 2012-07-30 2018-12-20 Medical & Biological Laboratories Co., Ltd. Monoclonal antibody against human midkine
WO2016013115A1 (ja) * 2014-07-25 2016-01-28 株式会社 リージャー 希釈生体試料成分の分析方法
CA3073515A1 (en) 2017-08-25 2019-02-28 Stoke Therapeutics, Inc. Antisense oligomers for treatment of conditions and diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3129793A (en) * 1991-11-08 1993-06-07 General Hospital Corporation, The Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
DE4312389A1 (de) * 1993-04-16 1994-10-20 Wolff Walsrode Ag Reflexionsreduzierte, verklebbare gereckte Folie als Fensterfolie für Briefumschläge
US5994524A (en) * 1994-07-13 1999-11-30 Chugai Seiyaku Kabushiki Kaisha Polynucleotides which encode reshaped IL-8-specific antibodies and methods to produce the same
US6048972A (en) * 1994-07-13 2000-04-11 Chugai Pharmaceutical Co., Ltd. Recombinant materials for producing humanized anti-IL-8 antibodies
CA2195450A1 (en) * 1994-07-18 1996-02-01 Kenneth J. Colley Antisense oligonucleotides of pleiotrophin
JPH0827021A (ja) * 1994-07-22 1996-01-30 Mitsui Toatsu Chem Inc 医薬組成物
JP3553655B2 (ja) * 1994-09-02 2004-08-11 喬 村松 ポリペプチドの製造法
US5670477A (en) * 1995-04-20 1997-09-23 Joseph F. Poduslo Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents
US5629284A (en) * 1995-07-24 1997-05-13 Meiji Milk Products Co., Ltd. Method for treating retinal diseases
JPH0995454A (ja) * 1995-10-02 1997-04-08 Meiji Milk Prod Co Ltd 抗潰瘍組成物
WO1999003493A1 (fr) * 1997-07-14 1999-01-28 Meiji Milk Products Co., Ltd. Medicaments contenant midkine en tant principe actif ou inhibiteurs desdits medicaments
CN1278184A (zh) * 1997-09-26 2000-12-27 吉田义弘 预防或治疗局部缺血性疾病的药剂
US8106009B2 (en) * 1997-09-26 2012-01-31 Medical Therapies Limited Pharmaceutical composition for preventing or treating ischemic diseases
EP1042850B1 (de) 1997-12-23 2001-11-14 Schleuniger Holding AG Abisoliervorrichtung
WO1999038971A1 (fr) * 1998-02-02 1999-08-05 Meiji Milk Products Co., Ltd. Proteine se liant a la midkine

Also Published As

Publication number Publication date
US7309695B2 (en) 2007-12-18
AU762437B2 (en) 2003-06-26
CN1324249A (zh) 2001-11-28
US20080107659A1 (en) 2008-05-08
JP4228111B2 (ja) 2009-02-25
EP1108436B1 (de) 2009-08-12
US7820160B2 (en) 2010-10-26
US20040077579A1 (en) 2004-04-22
KR20010103572A (ko) 2001-11-23
AU5305599A (en) 2000-03-14
ATE439146T1 (de) 2009-08-15
EP1108436A4 (de) 2002-05-29
KR100608276B1 (ko) 2006-08-02
WO2000010608A1 (fr) 2000-03-02
CN1222296C (zh) 2005-10-12
CA2341638A1 (en) 2000-03-02
CA2341638C (en) 2010-05-11
EP1108436A1 (de) 2001-06-20

Similar Documents

Publication Publication Date Title
BG106020A (en) Inhibitors of impdh enzyme
DE60005560D1 (de) Neuartiger p2x 7 rezeptor-antagonisten zur verwendung in der behandlung von entzündlichen, immuninduzierten erkrankungen oder erkrankungen des herz-kreislauf-systems
EE200300306A (et) Oksübensamiidi derivaadid, nende valmistamine ja kasutamine Xa-teguri inhibiitoritena ning neid sisaldav ravimpreparaat
DE60329316D1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
ATE556705T1 (de) Darreichungsform enthaltend taxol in kristalliner form
DK0810889T3 (da) Implantat
DE69941263D1 (de) Zusammensetzungen zur vorbeugung und behandlung der artheriosklerose und der restenose nach ptca
DE69738815D1 (de) Verwendung von Cyclooxygenase-2 Inhibitoren zur Behandlung und Vorbeugung von Neoplasia
DE69532687D1 (de) Pharmazeutische zusammensetzungen zur vorbeugung und behandlung der ulzerativen kolitis
HUP0302955A2 (hu) HMG-CoA reduktáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk koleszterinnel kapcsolatos betegségek kezelésére
DE60014035D1 (de) Zusammensetzung zur hautdesinfektion
WO2003070283A3 (en) Agent for inhibiting development or progress of proliferative diseases and especially cancer diseases and pharmaceutical composition containing said agent
ATE527261T1 (de) 7-aryl-3,9-diazabicycloä3.3.1ünon-6-en-derivate und ihre verwendung als renin-inhibitoren zur behandlung von bluthochdruck, herz-kreislauf- erkrankungen und nierenkrankheiten
DE602004028367D1 (de) Neue indolderivate als faktor xa-inhibitoren
NO20025810D0 (no) Faktor VIIA-inhibitoriske (tio)ureaderivater, deres fremstilling og anvendelse
BRPI0307808A2 (pt) composição inibidora da lipase
NO20045630L (no) Forbindelser for behandling av antraks og inhibering av letal faktor
DE60018704D1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
BRPI0410763A (pt) derivados de triazol como inibidores de fator xa
DE69821749D1 (de) Benzimidazol-derivate und ihre pharmazeutisch verträglichen salze
WO2005039629A3 (en) Caspase inhibitors as coating materiel for medical products for inhibiting restenosis
IL164674A (en) Catalytic deoxyribonucleic acid that cleaves pai-1 and uses thereof
DE69808607T2 (de) Verfahren zur verwendung von cyclooxygenase-2 hemmern zur behandlung und vorbeugung der demenz
DK1235850T3 (da) Umættede 14,15-cyclopropano-androstaner, fremgangsmåde til deres fremstilling og farmaceutiske præparater indeholdende disse forbindelser
GEP20033130B (en) Inhibitors of IMPDH Enzyme

Legal Events

Date Code Title Description
8364 No opposition during term of opposition